Blockbusters like Losec and Nexium have not been able to provide all gastroesophageal reflux disease (GERD) patients with sufficient disease control. Time has now come for the next leap forward in the treatment of acid related diseases. Cinclus Pharma’s clinical stage drug candidate X842 takes a new approach to provide improved management of esophagitis and GERD symptoms.
De-risked development program – phase II study in planning
X842 provides improved acid control
people in initial, niche target population
individuals exposed to the active metabolite of X842 in clinical trials
Team with experience from development of Losec and Nexium